TVM Capital Healthcare, an international healthcare expansion and growth capital firm, announced an equity investment in Human Longevity, Inc. (HLI), a San Francisco-based company also a global leader since 2013 in advancing precision medicine in the pursuit of healthy aging, also known as longevity medicine. The investment aims to support the company's growth within the U.S. market, as well as its expansion to the Kingdom of Saudi Arabia and Southeast Asia.
Founded by Dr. J. Craig Venter, one of the pioneers of the human genome sequencing effort, HLI builds on his vision for a longer, healthier life and the democratization of genomics to revolutionize the way we evade ‘avoidable disease’ and stay healthy longer. The company is recognized as a leader in the rapidly expanding industry of longevity medicine due to its deep expertise in genomics and other fields of precision medicine such as imaging, and its unmatched, longitudinal patient dataset built on decades of research in the field.
HLI is transforming healthcare from a reactive practice to a preventative, which enhances the quality of lives of individuals and also improves the efficiency and efficacy of the entire healthcare system. The company has proprietary tools for the detection of gene-disease associations, which includes HLI's artificial intelligence health risk and recommendation platform, and offers its clients pre-symptomatic diagnosis and customized treatments, detecting disease at a very early stage.
TVM Capital Healthcare brings extensive global investment experience combined with operating experience in the Middle East and Southeast Asia and a track record of building innovative healthcare companies. Through this investment provided by the Saudi Arabia-focused TVM Healthcare Afiyah Fund LP, which closed earlier this year and is the largest growth capital fund of its kind in the region, the firm will support HLI in its expansion, initially with a special focus on market entry in the Kingdom. The country's Vision 2030 and Health Sector Transformation Program call for an evolution of ‘sick care’ to true ‘health care,’ focusing on the most critical fields of oncology, neurology, metabolic syndrome, and diabetes, as well as cardiovascular and autoimmune disease.
Saudi Arabia is highly receptive to healthcare business models such as HLI and has been increasingly active in longevity science with several government-backed initiatives, including the Saudi Human Genome Program and the Revolution Foundation, a Riyadh-headquartered global non-profit organization, investing in scientific projects and life science companies in the longevity field.
Dr. J. Craig Venter, Co-Founder and Chief Scientific Advisor of Human Longevity, Inc., commented, "Human Longevity, Inc. is a health firm where the goal is to stay ahead of aging and illness. We believe this platform will save millions of lives and significantly reduce healthcare costs in the future. TVM Capital Healthcare's investment enables us to strengthen our position globally as the most data-backed longevity practice, as well as establishes our foothold in markets, like Saudi Arabia and SEA, that see the potential of our approach in preventive medicine and the huge impact it will have on changing the cost of medicine".